

## **Puma VCT 13 plc**

**4 April 2025**

### **Issue of Equity**

The Directors of Puma VCT 13 plc (the "Company") are pleased to announce that further to an offer for subscription (the "Offer") of ordinary shares of £0.0005 each in the Company ("Ordinary Shares") to raise up to £50,000,000, together with an over-allotment facility which has been exercised for up to a further £20,000,000, as set out in a prospectus dated 24 September 2024 (the "Prospectus"), the Company has today made a further allotment of 2,960,187 Ordinary Shares pursuant to the Offer.

In accordance with the allotment formula set out in the Prospectus, the offer prices at which the Ordinary Shares were allotted were in the range of £1.2357 to £1.3271 per Ordinary Share, which have been calculated by reference to the most recently announced net asset value per Ordinary Share (being 123.57p (unaudited) as at 13 January 2025 (as announced on 13 January 2025)).

Following this allotment, the total number of Ordinary Shares in issue is 163,708,497. Therefore, the total number of voting rights in the Company is 163,708,497. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Application will be made for the Ordinary Shares so allotted to be admitted to the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities, and dealings are expected to commence on or around 8 April 2025. Definitive documents of title are expected to be despatched within 10 business days of allotment.

For further information please contact:

Eliot Kaye  
Puma VCT 13 plc  
020 7408 4050

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEIIMRTMTMMBRA